Bayer aims at J&J and Pfizer with new prostate cancer drug

The FDA has approved Bayer and Orion’s prostate cancer drug darolutamide in the early stages of the disease as it takes on rivals such as Johnson & Johnson.

EMA starts review of Xtandi in hormone-sensitive prostate ca...

Seattle Genetics and Astellas file bladder cancer drug in US

Seattle Genetics and Astellas have filed their antibody-drug conjugate enfortumab vedotin with the US drug regulator for advanced bladder cancer, after failure of chemotherapy and immunothe

Why pharma needs honest patient dialogue

Astellas Pharma US president Percival Barretto-Ko talks with Dr Paul Tunnah about drug pricing, collaboration and improving the patient experience.

Astellas/Seattle Genetics target advanced bladder cancer wit...

Roche and Merck & Co have got their respective immunotherapies Tecentriq and Keytruda approved in bladder cancer – but the problem of low response rates remains. At the ASCO an